REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/07/2025
Back to search
Official data from USPTO
RIBOCYTOKINE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
RIBOCYTOKINE
ST13
US500000079266179Class
1, 5, 40, 42, 44
Filing
79266179
Registration
6093112
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
07/08/2025
Trademark type
Word
Nice classes
1, 5, 40, 42, 44
Filing date
04/30/2019
Registration date
07/07/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/07/2020
Last transaction
07/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
27
Owner location
DE
Examiner
GILBERT, REBECCA
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
B. S. (pessoa física)
BioNTech RNA Pharmaceuticals GmbH
Representatives
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical agents for laboratory usein particular nucleic acidspeptides and proteins; chemical agents for the production of anticancer drugs and vaccinesin particular nucleic acidspeptides and proteins
Class 5
Pharmaceutical products for treating cancerous diseasesinfections and autoimmune disorders
Class 40
Treatment and conversion of materialcustom manufacturing of chemical and biochemical preparations; custom manufacturing of biopharmaceuticalschemical agents for laboratory usein particular nucleic acidspeptides and proteinspharmaceutical products of all kindsin particular for treating cancerous diseasesinfections and autoimmune disordersof chemical agents for the production of anticancer drugs and vaccinesin particular nucleic acidspeptides and proteins; custom manufacturing of therapeutic pharmaceuticals
Class 42
Scientific research for medical purposesin particular for developing treatment concepts for cancerous diseasesinfections and autoimmune diseases
Class 44
Medical and veterinary services in connection with the treatment of cancerous diseasesinfections and autoimmune disorders
Publications
History of USPTO decisions and trademark events.
31 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/31/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/30/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
05/30/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/30/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/30/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/30/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/30/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/19/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/10/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/30/2020
FIMP
FINAL DISPOSITION PROCESSED
10/29/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/07/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
07/07/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/21/2020
PUBO
PUBLISHED FOR OPPOSITION
04/21/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/01/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/19/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/18/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/18/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/18/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/16/2020
RFNT
REFUSAL PROCESSED BY IB
10/12/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/20/2019
RFRR
REFUSAL PROCESSED BY MPU
09/20/2019
MAFR
APPLICATION FILING RECEIPT MAILED
09/13/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/10/2019
CNRT
NON-FINAL ACTION WRITTEN
09/09/2019
DOCK
ASSIGNED TO EXAMINER
09/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/29/2019
Continuous trademark protection
Get notified about every new filing that threatens RIBOCYTOKINE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.